Abstract 624P
Background
Most cancer immunotherapy research focuses on gene-level expression, often bypassing the key role of alternative splicing in producing various isoform transcripts. Alternative splicing contributes significantly to tumor heterogeneity, progression, and therapy response1-3. Understanding these dynamics is paramount for advancing personalized treatment strategies.
Methods
1. Data Integration - Integrated multi-omics data from diverse tumor types. - Focused on immune cells within the tumor microenvironment. 2. Sample collection - Gathered data from both pre- and post-immunotherapy treated patients. - Included clinical response details for comprehensive insights. 3. Isoform analysis - Constructed a single-cell isoform atlas capturing the landscape of alternative splicing events and isoform expression profiles across a vast array of cancers. - Investigated patterns of isoform diversity/plasticity: - Within and between different cancer types. - Between pre- and post-treatment scenarios. - Among responders vs. non-responders.
Results
Pan-cancer isoform signatures - For each cancer type and at the pan-cancer level, the isoform patterns of immune cell types linked with oncogenic processes between (i) healthy and cancer; (ii) pre- and post-treatment; (iii) immunotherapy responders and non-responders.
Conclusions
Our pan-cancer single-cell isoform atlas offers a groundbreaking perspective on isoform dynamics in cancer immune environment, enriching our comprehension of tumor intricacies and bolstering efforts toward precision oncology for individualized patient care.
References: 1. Climente-González, H., Porta-Pardo, E., Godzik, A. & Eyras, E. The Functional Impact of Alternative Splicing in Cancer. Cell Reports 20, 2215-2226 (2017). https://doi.org:https://doi.org/10.1016/j.celrep.2017.08.012.
2. Zhang, Y., Qian, J., Gu, C. & Yang, Y. Alternative splicing and cancer: a systematic review. Signal Transduction and Targeted Therapy 6, 78 (2021). https://doi.org:10.1038/s41392-021-00486-7
3. Bonnal, S. C., López-Oreja, I. & Valcárcel, J. Roles and mechanisms of alternative splicing in cancer - implications for care. Nature Reviews Clinical Oncology 17, 457-474 (2020). https://doi.org:10.1038/s41571-020-0350-x
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
L. Pan.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
496P - Fruquintinib plus sintilimab in patients (pts) with advanced non-small cell lung cancer (NSCLC) with PD-L1-positive expression: A multicenter, single-arm phase II study
Presenter: Shun Lu
Session: Poster Display
Resources:
Abstract
497P - Sintilimab in combination with anlotinib in advanced NSCLC treated with first-line PD-1 antibodies: An open, single-arm, phase II trial
Presenter: Ying Jin
Session: Poster Display
Resources:
Abstract
498P - Frailty-adjusted life expectancy and survival in older lung cancer patients: A large-scale electronic health-record based study
Presenter: Thao Tu
Session: Poster Display
Resources:
Abstract
499P - Long-term survival and treatment (tx) patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer (NSCLC): Japanese cohort of a global real-world (rw) observational study
Presenter: Daichi Fujimoto
Session: Poster Display
Resources:
Abstract
500P - The effectiveness and safety of durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small cell lung cancer: Real-world, multicenter, observational study (NEJ056)
Presenter: Hidehito Horinouchi
Session: Poster Display
Resources:
Abstract
501P - One-year survival outcomes of unresectable stage III non-small cell lung cancer patients who underwent PD-1 inhibitor plus chemo as induction therapy
Presenter: Xin Wang
Session: Poster Display
Resources:
Abstract
502P - Impact of sarcopenia on the outcome of patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab
Presenter: Kentaro Tamura
Session: Poster Display
Resources:
Abstract
503P - Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with locally advanced NSCLC
Presenter: TSUYOSHI HIRATA
Session: Poster Display
Resources:
Abstract
504P - Real-world outcomes with induction systemic therapy for stage III in eligible for upfront local therapy: Pre vs post immunotherapy era in a tertiary referral centre
Presenter: Praveen Kumar Marimuthu
Session: Poster Display
Resources:
Abstract
505P - Neoadjuvant PD-1 inhibitor (tislelizumab) plus platinum–etoposide in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Junjie Hu
Session: Poster Display
Resources:
Abstract